CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $2.12B, above the global median of $1.15B
- FinancialsAltman Z-Score 13.18: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.12BUSDvs all stocks (USD)
Revenue (TTM)
238.10MUSDvs all stocks (USD)
Profit Margin
-13.21%vs Medical Devices peers
Beta
1.09xvs all stocks
52-Week Change
243.24%vs all stocks
Market Capitalization
2.12BUSDvs all stocks (USD)
Enterprise Value
1.98BUSDvs all stocks (USD)
Forward P/E
54.61xvs Medical Devices peers
Price to Sales (TTM)
8.88xvs Medical Devices peers
Price to Book (MRQ)
8.64xvs Medical Devices peers
Enterprise to Revenue
8.31xvs Medical Devices peers
Gross Margin
75.16%vs Medical Devices peers
Profit Margin
-13.21%vs Medical Devices peers
Operating Margin
-4.61%vs Medical Devices peers
Return on Assets (TTM)
-2.32%vs Medical Devices peers
Return on Equity (TTM)
-17.96%vs Medical Devices peers
Revenue (TTM)
238.10MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.00USDUpdated Jul 18, 2026Quarterly Revenue Growth
26.60%vs Medical Devices peers
Gross Profit (TTM)
178.61MUSDvs all stocks (USD)
EBITDA (TTM)
826.00KUSDvs all stocks (USD)
Net Income (TTM)
-31.45MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
26.56%vs Medical Devices peers
Operating Cash Flow (TTM)
15.56MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
18.29MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Medical Devices peers
Revenue
225.21MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
57.85MUSDFY2025 · Dec 31, 2025Gross Profit
167.35MUSDFY2025 · Dec 31, 2025Operating Income
-7.85MUSDvs all stocks (USD)
Pre-tax Income
-15.70MUSDFY2025 · Dec 31, 2025Net Income
-15.70MUSDFY2025 · Dec 31, 2025EBIT
-8.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
826.00KUSDFY2025 · Dec 31, 2025Research & Development
32.88MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
142.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.70MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
46.05MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
46.05MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-15.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
10.26MUSDFY2025 · Dec 31, 2025Free Cash Flow
6.52MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
39.55MUSDFY2025 · Dec 31, 2025Interest Paid
6.81MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-15.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
8.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
30.11MUSDFY2025 · Dec 31, 2025Other Non-cash Items
891.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.46MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-11.08MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.75MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.85MUSDFY2025 · Dec 31, 2025Purchase of Investments
-13.72MUSDFY2025 · Dec 31, 2025Sale of Investments
14.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.47MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-32.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-32.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
53.15MSharesUpdated Jul 18, 2026Float Shares
52.02MSharesUpdated Jul 18, 2026Shares Short
4.63MSharesUpdated Jul 18, 2026Short Ratio
3.24daysvs all stocks
Short % of Shares Outstanding
10.09%vs all stocks
% Held by Insiders
2.19%vs all stocks
% Held by Institutions
93.86%vs all stocks
Total Cash (MRQ)
101.60MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.91USDUpdated Jul 18, 2026Total Debt (MRQ)
20.64MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0843xvs Medical Devices peers
Current Ratio (MRQ)
7.10xvs Medical Devices peers
Book Value per Share (MRQ)
4.61USDUpdated Jul 18, 2026Total Assets
221.69MUSDvs all stocks (USD)
Total Current Assets
120.42MUSDFY2025 · Dec 31, 2025Total Liabilities
92.84MUSDFY2025 · Dec 31, 2025Total Non-current Assets
101.27MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.28MUSDFY2025 · Dec 31, 2025Total Current Liabilities
23.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
35.55MUSDFY2025 · Dec 31, 2025Other Short-term Investments
5.98MUSDFY2025 · Dec 31, 2025Accounts Receivable
26.17MUSDFY2025 · Dec 31, 2025Inventory
42.37MUSDFY2025 · Dec 31, 2025Accounts Payable
2.89MUSDFY2025 · Dec 31, 2025Short-term Debt
2.37MUSDFY2025 · Dec 31, 2025Long-term Debt
65.26MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
141.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
472.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-306.96MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
128.85MUSDvs all stocks (USD)
52-Week Low
11.27USDUpdated Jul 18, 202652-Week High
46.95USDUpdated Jul 18, 202652-Week Change
243.24%vs all stocks
Beta
1.09xvs all stocks
50-Day MA
42.37USDUpdated Jul 18, 2026200-Day MA
32.67USDUpdated Jul 18, 2026Avg 10-Day Volume
1.41MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.47MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.6400USDUpdated Jul 18, 2026Other Income / Expense
-152.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.75Profit Margin: -0.13
Financial Health
Altman Z-Score 13.18: safe zoneNotable
Altman Z-Score: 13.18
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $2.12B, above the global median of $1.15BNotable
Market cap (USD): 2,119,136,286Global Median: 1,146,734,693.424
Levered free cash flow is $18.29M, above the global median of $16.24MNotable
Levered free cash flow (USD): 18,294,250Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hanall Biopharma Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinyu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule